Financial Report January - December 2001

FINANCIAL STATEMENT 1 January - 31 December 2001 · Market breakthrough for antibody library n-CoDeR(TM) Partnership agreement with Oxford GlycoSciences plc., GlaxoSmithKline Biologicals S.A., Novo Nordisk A/S and others · Increased demand for manufacturing and development services Agreement with new customers ImmunoGen Inc. and Igeneon AG · BioInvent's shares floated on the O-list of the Stockholm Exchange on 12 June · Net revenue for January - December 2001: SEK 58.3 million (24.1) · Loss after net financial items for January - December 2001: SEK-43.5 million (-34.5) · Cash flow from current operations and investment activity 2001: SEK -74.8 million Liquid funds at year-end: SEK 338.7 million This report is based on the audited annual accounts. Contact Questions about this report will be answered by: Svein Mathisen, President and CEO, tel. +46 (0)46 286 85 67 or Jonas Källmén, CFO, tel. +46 (0)46 286 38 12. Financial reports are also available at www.bioinvent.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00560/wkr0002.doc The full report http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00560/wkr0003.pdf The full report